Array Biopharma Inc.

Genentech, Inc.

Astrazeneca Ab

Peter J Mohr

James F Blake

Mark Joseph Chicarelli

Bin Wang

Indrani W Gunawardana

Eli M Wallace

Huifen Chen

Jacob Bradley Schwarz

Li Ren

David A Moreno

Michael Lyon

John Joseph Gaudino

Yvan Le Huerou

Rustam Ferdinand Garrey

Lewis J Gazzard

Kirk D Robarge

Aihe Zhou

Michelle Lamb

Tao Wang

Jonas Grina

Dingwei Yu

Adam Wade Cook

Andrew T Metcalf

Kevin W Hunt

Brad Newhouse

Allen A Thomas

Jane Schmidt

Tony P Tang

Paul D Lyne

Robert J Kaus

Christopher Stephen Siedem

Jason Demeese

Gabrielle R Kolakowski

Steven Armen Boyd

Allison L Marlow

Yongxin Han

Erik James Hicken

Samuel S Kintz

Steven Mark Wenglowsky

Audrey Davies

Steve Do

Indrani W Gunwardana

Audrey Molina

Christopher S Siedem

John Gaudino

Paul Lyne

Jacob Schwarz

Kirk Robarge

Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Serine/threonine kinase inhibitors

Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Compounds of Formula I are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Pyrrolopyridines as kinase inhibitors

Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such diseases, or associated pathological conditions are disclosed. 

Compounds having the formula (I) wherein R, R, Rand Ar as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders. 

Substituted quinazolines as serine/threonine kinase inhibitors

Compounds having the formula I wherein Z, ZZZ, R, Rand Rand as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders. 

Compounds of Formula (I) are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula (I) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

This invention relates to novel compounds having the formula (I): and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.

Pyrazolylaminopyridine derivatives useful as kinase inhibitors

Growing community of inventors

Boulder, CO, United States of America

Peter J Mohr